Period Power: Could Your Sanitary Pad Be the Future of Cervical Cancer Screening?
For decades, cervical cancer screening has relied on a clinic visit for a Pap smear or HPV test. But groundbreaking research suggests a simpler, more accessible future may be on the horizon: testing menstrual blood collected from sanitary pads for signs of HPV, the virus responsible for the vast majority of cervical cancers.
The Science Behind the ‘Minipad’
A recent study published in the British Medical Journal demonstrated that testing a blood sample strip within a sanitary pad – dubbed a “minipad” – could be as effective as traditional clinician-collected samples for HPV detection. Researchers tested over 3,000 participants in China between 2021 and 2025, finding comparable diagnostic accuracy. Over 400 participants with positive screening results were referred for further investigation.
Accessibility and Convenience: Addressing Screening Barriers
The potential impact of this innovation is significant. Currently, one in three women and people with a cervix don’t attend scheduled cervical screenings. Reasons range from discomfort and anxiety to logistical challenges and cultural barriers. A home-based test could overcome many of these hurdles.
“Any test they can do at home will support people,” says Helen Hyndman, lead nurse at The Eve Appeal, a gynaecological cancers charity. The convenience could be particularly beneficial for individuals with physical needs, learning disabilities, or those who have experienced trauma related to previous screenings.
China Leads the Way in HPV Prevention
This research arrives alongside significant strides in HPV vaccination efforts in China. In November 2025, China added the HPV vaccine to its national immunization program, offering free, two-dose vaccinations to girls born on or after November 10, 2011, who have reached 13 years of age. This move, applauded by the World Health Organization, aims to protect millions from cervical cancer. China also rolled out its first homegrown nine-valent HPV vaccine in June 2025.
Challenges and Considerations
Despite the promising results, several challenges remain. The study acknowledged limitations, including a small sample size and a low baseline rate of cervical lesions. A key concern is that the test relies on menstrual blood, excluding those who do not menstruate – including women who are perimenopausal or using certain forms of contraception like the Mirena coil, Depo-Provera, or the implant.
Jenny Greenfield, trustee and director of UK Cervical Cancer, also raised questions about the practicality of the method. “We need to consider how many people use pads, a lot of people use tampons. Can [this be done] with a tampon?” she asked.
Beyond the Pad: Expanding Access Through Self-Sampling
The push for greater accessibility isn’t limited to menstrual blood testing. England is already offering HPV self-sampling kits to under-screened women, providing another at-home option for detecting the virus. This aligns with the government’s goal of eliminating cervical cancer by 2040.
Future Trends in Cervical Cancer Prevention
The convergence of HPV vaccination programs, self-sampling kits and innovative testing methods like the “minipad” points to a future where cervical cancer screening is more proactive, personalized, and accessible. Expect to notice:
- Increased adoption of self-sampling: More countries will likely follow England’s lead, offering HPV self-sampling as a routine screening option.
- Technological advancements: Further refinement of at-home testing technologies, potentially including smartphone-based analysis and instant results.
- Personalized screening schedules: Risk-based screening strategies, tailoring the frequency of tests based on individual HPV status and risk factors.
- Greater emphasis on vaccination: Continued efforts to increase HPV vaccination rates globally, particularly among underserved populations.
FAQ
Q: Is this test available now?
A: The research is promising, but the test is not yet widely available. Further studies and regulatory approvals are needed.
Q: Who can use this test?
A: Currently, the test is designed for individuals who menstruate. It is not suitable for those who do not menstruate or have very light periods.
Q: Does this replace traditional screening?
A: It may offer an alternative for some, but it’s important to continue attending recommended cervical screening appointments when invited.
Q: What is HPV?
A: Human papillomavirus (HPV) is a very common virus. Some types of HPV can cause cervical cancer.
Did you know? Cervical cancer is one of the few cancers that can be largely prevented through vaccination, screening, and treatment.
Pro Tip: Talk to your healthcare provider about your individual risk factors for cervical cancer and the best screening options for you.
Stay informed about the latest advancements in women’s health. Visit The Eve Appeal to learn more about cervical cancer prevention and support.
